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ABSTRACT 
Background: In patients with pancreatic cancer 15-20% are resectable at the time of 
diagnosis. Still another 8-20% are found to be unresectable at laparotomy. The optimal 
intraoperative strategy for this group is not known. Some patients experience early 
recurrence of the cancer indicating undetected advanced disease at the time of surgery. 
We need tools to detect these patients, who do not benefit from surgery. Pancreatic 
surgery is still associated with a high burden of complications, postoperative pancreatic 
fistula (POPF) being the potentially most harmful. The overall aim of this thesis project 
was to investigate whether modification of existing surgical techniques and preoperative 
routines can improve postoperative outcome in patients with pancreatic tumours. 
Methods: Paper I was a retrospective study comparing postoperative outcome for patients 
diagnosed with unresectable periampullary cancer at laparotomy and treated either with 
endoscopically placed stents on demand or prophylactic double bypass surgery. Paper II 
was a prospective study where patients treated with PD for suspected periampullary 
cancer had lymph node (Ln) 8a separately analysed. Tumour status of the lymph node was 
compared regarding overall survival (OS). Paper III was an RCT randomizing patients 
planned for DP to stapler division of the pancreas with or without stapler reinforcement, 
looking at POPF frequency postoperatively. Paper IV is a registry-based study that 
retrieved data from the Swedish National Pancreatic and Periampullary Cancer Registry 
to compare two pancreatic reconstructions after PD, pancreatogastrostomy (PG) and 
pancreatojejunostomy (PJ), regarding POPF development.  
Results: Paper I – There were more complications and longer hospital stay in the surgery 
group compared to the group treated with stent on demand. In addition a prophylactic 
gastroenteric anastomosis did not prevent future gastric outlet obstruction. Paper II - 
Tumour growth in Ln8a is associated with a substantial reduction of OS. Paper III – No 
differences in POPF between the study groups were observed. Paper IV - The PJ group 
had significantly more clinically relevant POPF and more severe complications than the 
PG group. 
Conclusions: Patients with unresectable periampullary malignancies can safely be 
managed with endoscopic drainage on demand and with lower morbidity and shorter 
hospital stay than with surgical prophylactic bypass. Tumour involvement of Ln8a is 
associated with short OS. Reinforcement of the stapler line in DP does not reduce POPF 
frequency. PG might to be a safer pancreatic reconstruction than PJ due to less risk of 
developing clinically relevant POPF.  
 
Keywords: pancreatoduodenectomy, distal pancreatectomy, pancreatogastrostomy, 
pancreatojejunostomy, postoperative pancreatic fistula, lymph node 8a, palliative surgery 
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Sammanfattning på svenska 
Bakgrund  
Patienter med cancer i bukspottkörteln, eller pankreas, söker vård sent i 
sjukdomsförloppet eftersom sjukdomen ger få och diffusa symptom från 
början. Vid diagnostillfället har de flesta av tumörerna hunnit sprida sig och 
endast 15-20% har möjlighet till bot, vilket sker genom operation. Vid 
operation finner man i ytterligare 8-20% att tumören spridit sig varvid 
operation inte ger någon förlängd överlevnad. Vilken handläggning som är 
bäst för denna patientgrupp är ännu oklart. En grupp opererade patienter 
återfår sin cancer redan under första året vilket talar för att tumören hade 
oupptäckt spridning redan vid operationen. Denna patientgrupp har sannolikt 
inte nytta av operationen och vi saknar idag verktyg för att hitta dem under 
utredningsfasen. Operationer på bukspottkörteln är, trots uttalade 
förbättringar de senaste 20 åren, förenade med hög komplikationsrisk vilket 
kan försena återhämtningen efter operation. 
Målsättning 
Det övergripande syftet med detta avhandlingsprojekt var att undersöka 
huruvida modifiering av befintliga kirurgiska tekniker och utredningsrutiner 
kan förbättra utfallet efter operation för patienter med tumörer i 
bukspottkörteln. 
Metod och Resultat  
I delarbete I jämfördes två behandlingsstrategier vid fynd av spridd cancer i 
samband med operation. På Sahlgrenska Universitetssjukhuset görs 
förebyggande förbikoppling av tumören, vid samma operationstillfälle, och 
på Skånes Universitetssjukhus avslutas operationen och förbikoppling görs 
när symptom uppstår, med hjälp av gastroskopi och s.k. stent från insidan. 
Studiegruppen utgjordes av ca 70 patienter från respektive sjukhus. I den 
opererade gruppen drabbades 67% av komplikationer och 31% i den 
konservativt behandlade gruppen. Vårdtiden i samband med operationen var 
också längre i den opererade gruppen, 14 respektive 8 dagar, men behovet av 
sjukhusvård under resterande livstid skiljde sig inte åt mellan grupperna. 
Operation gav alltså inte någon fördel framför konservativ behandling men 
den ger fler komplikationer.  
I delarbete II undersöktes tumörförekomst i en av lymfkörtlarna (körtel 8a) 
vid bukspottkörteln, hos patienter som opererades för misstänkt cancer i 
bukspottkörteln. Gruppen med tumör i körtel 8a, 16 patienter, jämfördes med 
gruppen utan tumör i körtel 8a, 71 patienter, avseende överlevnad. Det visade 
sig att tumörförekomst i körtel 8a var associerat med avsevärt förkortad 
överlevnadstid. 
I delarbete III jämfördes två grupper som opererade bort vänster sida av 
bukspottkörteln avseende utveckling av bukspottkörtelfistlar efter 
operationen. Grupperna randomiserades till antingen delning av 
bukspottkörteln på sedvanligt vis eller med tillägg av ett 
förstärkningsmaterial vid delningsstället. Förekomst av bukspottkörtelfistlar 
efter operationen jämfördes och det visade sig inte vara någon skillnad 
mellan de båda behandlingsgrupperna. 
Delarbete IV är en registerstudie med data från det nationella registret för 
bukspottkörtelcancer. Vid borttagande av högra sidan av bukspottkörteln 
måste den kvarvarande bukspottkörteln sys till magtarmkanalen. Detta görs 
oftast till tunntarm (PJ) eller magsäck (PG). Vi jämförde patienter opererade 
mellan 2010 och 2016 på ovanstående sätt, 1118 patienter med PJ och 567 
patienter med PG, avseende förekomst av bukspottkörtelfistlar och andra 
komplikationer efter operation. PJ-gruppen hade fler fistlar och andra 
komplikationer än PG-gruppen. 
Slutsatser 
• Patienter med upptäckt av cancer som inte kan botas, under 
operation, kan på ett säkert sätt handläggas med s.k. stentning vid 
symptom, med färre komplikationer och kortare vårdtid som resultat 
jämfört med operation.  
• Tumörförekomst i Ln8a är associerat med kort förväntad överlevnad.  
• Användning av ett förstärkningsmaterial på bukspottkörtelns 
delningsställe vid vänstersidig bukspottkörteloperation leder inte till 
färre bukspottkörtelfistlar. 
• PG skulle kunna vara en säkrare bukspottkörtelrekonstruktion, efter 
högersidig bukspottkörteloperation, än PJ på grund av lägre risk att 
utveckla bukspottkörtelfistlar efter operation. 
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1 Introduction 
The pancreas is a gland, situated in the upper abdomen that consists of both 
endocrine cells, forming the islets of Langerhans, and exocrine cells, forming 
acini. The endocrine cells secrete the hormone insulin, necessary in 
carbohydrate (sugar) metabolism, into the blood circulation. The exocrine 
cells discharge digestive enzymes and bicarbonate into the gut.  
Some of the most common diseases in the pancreas are acute or chronic 
inflammation (pancreatitis), diabetes and tumours2. The most common 
malignant tumour is pancreatic cancer (cancer in the exocrine cells) which is 
one of the most deadly cancers known. It constitutes 2% of the yearly 
incidence of cancer but is the fourth most common cause of cancer-related 
death in economically developed countries 3 4. 
Symptoms of pancreatic cancer are initially vague and unspecific, and this 
contributes to a delayed diagnosis. Cardinal signs are unexplained weight 
loss, abdominal pain, sometimes radiating to the back, and jaundice5, 6. A first 
episode of pancreatitis or recent onset of diabetes can also signal 
development of a pancreatic cancer7.  
Surgery is the only potentially curative treatment for pancreatic cancer but 
unfortunately, only ≈20% of patients are considered resectable after work-up. 
Even when the patient is treated with surgery, and adjuvant chemotherapy, 
the five-year survival is poor (14-26%)8, 9 10, 11 with a median survival time of 
only 14-22 months12-14.  
My thesis project was undertaken to elucidate various aspects of surgical 
approaches to tumours of the pancreas in order to improve work-up and 
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selection of patients taken to surgery, to reduce postoperative complications 
and thereby improve recovery. 
The description of surgical methods in this thesis, curative resections and 
palliative operations, refers to patients with suspected pancreatic or 
periampullary cancer or other lesions in need of resection.  
1.1 Historical perspective of pancreatic cancer 
surgery 
In 1898 Codivilla, an Italian surgeon, performed the first 
pancreatoduodenectomy (PD), although the patient died after 18 days. The 
Swedish surgeon Dahl later performed the first Roux-en-Y 
choledocojejunostomy in 1908. The first successful regional resection of the 
head of the pancreas was performed by Kausch, a German surgeon, in 1909 
and was reported in 1912. The operative procedure of 
pancreatoduodenectomy was further developed in the 1930s by the American 
surgeon Whipple. It was initially a two-stage operation, where the first 
operation was performed to relieve jaundice and thereby restore coagulation 
and fat digestion, with a cholecystogastrostomy. The pancreatoduodenectomy 
was done some weeks later with duodenoduodenostomy and pancreatic 
exclusion15. The procedure was developed into a one-stage operation in 1941, 
now with a choledocojejunostomy16. This development was facilitated by the 
discovery of and preoperative treatment with vitamin K and bile salts. It was 
not until the 1950s that the pancreatoenteric anastomosis became routine10. 
Whipple performed 37 procedures during his career17. During the 1950s and 
1960s, extending into the 1970s, pancreatoduodenectomy did not become 
popular as a treatment modality because of the high mortality of about 25%18-
20. The development of high volume centres came in the 1980s and 1990s, 
and mortality has gradually dropped to the present 3-5%21. 
Johanna Hansson Wennerblom 
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1.2 Pancreatic and periampullary carcinoma 
Pancreatic ductal adenocarcinoma (PDAC), often just called pancreatic 
cancer, comprises approximately 80% of cancers in the pancreas (Table 1). 
The periampullary region is situated in the head of the pancreas, where the 
intrapancreatic bileduct, the distal pancreatic main duct, the ampulla (of 
Vater) and the second portion of the duodenum join together anatomically. 
Tumours arising in this area, within 2 cm of the major papilla, are called 
periampullary cancers22. Although these tumours have different origins, it is 
difficult to tell them apart preoperatively and their proximity within that 
confined region generally dictates a common operative approach. The most 
common of the four is PDAC (Table 1).  
 
1.2.1 Other malignant and premalignant lesions of the 
pancreas 
The second most common solid tumour in the pancreas after PDAC 
(incidence in Sweden ≈2%, see Table 1) is the neuroendocrine tumour 
(PanNET) which is malignant but less aggressive than pancreatic 
adenocarcinoma, with a ten-year survival rate of 45%7. Localized disease is 
often treated with surgery whereas systemic treatment is the choice when 
metastases are present23, 24.  
 
The cystic neoplasms of the pancreas are intraductal papillary mucinous 
neoplasm (IPMN), mucinous cystic neoplasm (MCN), solid pseudo papillary 
neoplasm (SPN) and serous cystic neoplasm (SCN). In main-duct IPMN 45% 
harbour an invasive component, whereas in side-branch IPMN 25% progress 
to at least high-grade dysplasia and 17% have at least some invasive 
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component25. MCN has an estimated risk of malignancy of 10-50%26. SPN is 
a low-grade malignant neoplasm, curatively treated with surgery27 and SCN 
is almost always benign28. 
1.2.2 Epidemiology 
In Sweden approximately 1500 patients/year are diagnosed with pancreatic or 
periampullary cancer, with pancreatic cancer of the head being the most 
common (Table 1).  Of these 20-25% are considered to have curable disease, 
meaning no distant metastases and no locally advanced tumour growth, 
whereas 50% have distant metastases29, 30.  
Table 1.  Pancreatic and periampullary tumours reported in 2016 to the Swedish 
Cancer Registry 31. n (%). 
 
 
1.2.3 Aetiology 
Risk factors for pancreatic cancer can be divided into hereditary and non-
hereditary ones. Among the latter increasing age is the strongest risk factor 
followed by smoking, with a more than two-fold increased risk for current 
smokers32.  Long-standing type 2 diabetes has a 1.5-fold increased risk of 
 2016 
Malignant tumours Pancreas 1413 (78.2) 
Caput (head) 716 (39.6) 
Corpus (body) 213 (12.8) 
Cauda (tail) 174 (9.6) 
Other location 292 (16.2) 
Extrahepatic bileduct 157 (8.7) 
Duodenum 104 (5.8) 
Ampulla of Vater (papilla) 91 (5.0) 
Pancreatic Neuroendocrine tumours  42 (2.3) 
Total 1807 (100) 
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pancreatic cancer whereas recent-onset diabetes may be a sign of pancreatic 
cancer33, 34. Other known risk factors are obesity35, heavy alcohol 
consumption36 and chronic pancreatitis37. Recent pancreatitis may instead be 
a sign of undetected pancreatic neoplasm7.  
Hereditary pancreatic cancer consists of cancer susceptibility syndromes, 
where mutations are known and often associated with several kinds of cancer 
(e.g. BRCA2, PALB2, and others), and in families with two or more 
pancreatic cancers in first-degree relatives, without known mutations38. The 
latter make up at least 3% of the pancreatic cancers39, 40.  
 
 
 
 
 
 
 
1.2.4 Diagnosis and staging 
In patients with an acute onset of symptoms, such as discovery of jaundice, 
radiological diagnostics often starts with an abdominal ultrasound, with a 
sensitivity of 50-90%41, 42. However, once there is a strong suspicion of 
Figure 1. Pancreas and the periampullary region. Reprinted with permission,  
Ó Corinne Sandone, Johns Hopkins University. 
Duodenum 
Common bile duct 
Pancreas 
Superior mesenteric vein 
Superior mesenteric artery 
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pancreatic cancer the preferred work-up is abdominal computed tomography 
(CT) with pancreas protocol, meaning intravenous and oral contrast and 
series taken before contrast and during arterial and venous phase separately. 
This will give information about the tumour, venous and arterial engagement, 
and signs of distant tumour engagement42. Pancreatic cancer primarily 
metastasizes to the liver, abdomen and the lungs43. To detect possible 
pulmonary metastases the work-up is completed with a thoracic CT. In spite 
of high quality imaging, metastatic disease is found during laparotomy in at 
least 16% of patients deemed resectable31, 44.  
In selected cases, further information can be retrieved from magnetic 
resonance imaging (MRI) e.g. evaluation of unclear tumours, cystic lesions or 
the pancreatic duct, suspected small metastases in the liver or peritoneal 
carcinomatosis42, 45, 46. In addition, endoscopic ultrasound (EUS) can add to 
differential diagnostics of unclear tumours and fine needle aspiration or 
biopsy for histopathology. Positron Emission Tomography (PET) has been 
extensively evaluated as a diagnostic tool but so far not exceeded CT in 
accurately separating benign or advanced malignant pancreatic disease from 
resectable pancreatic cancer47. There are no reliable tumour markers for 
pancreatic cancer to be used as screening tools, but the carbohydrate antigen 
19-9 (CA19-9) can be used to monitor treatment response48. 
The tumour can now be staged according to the TNM classification 49 and 
evaluated regarding resectability50. The performance status of the patient 
determines operability. All this together will result in a treatment 
recommendation preferably decided in a multidisciplinary treatment board, as 
recommended by many authors51, 52.  
Unfortunately, the current radiologic work-up has a low sensitivity in 
diagnosing metastatic lymph node engagement53. Furthermore, this is hard to 
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diagnose even macroscopically, during surgery54. Pathologic engagement of 
Ln’s is possibly better addressed with a biopsy or frozen section. 
1.2.5 Treatment 
Surgery 
Pancreatoduodenectomy 
Patients with a resectable tumour (no metastases, no or <180o venous 
engagement of the portal/superior mesenteric veins, no arterial engagement) 
of the head and uncinate process of the pancreas are treated with a 
pancreatoduodenectomy (PD) including resection of the extra hepatic bile 
ducts and gallbladder, duodenum, distal stomach and the pancreatic head. 
This procedure is also called a Kausch-Whipple operation55.  
An alternative resection is to spare the stomach and perform a pylorus 
preserving PD (PPPD) with division of the duodenum distal to the pylorus. 
Figure 2. Pancreatoduodenectomy, here pylorus preserving. Reprinted with 
permission, Ó Corinne Sandone, Johns Hopkins University 
Johanna Hansson Wennerblom 
8 
The outcome for these two operations is equivalent56 (Figure 2).  
Regional lymph nodes (Lns) are resected en bloc, as defined by the 
International Study Group on Pancreatic Surgery (ISGPS)11.  
On reconstruction, the continuity is re-established with three anastomoses: 
hepaticojejunostomy (end-to-side), gastro or duodenojejunostomy (depending 
on resection with PD or PPPD), and pancreatic anastomosis to either the 
jejunum (pancreatojejunostomy, PJ) or the stomach (pancreatogastrostomy, 
The prevailing anastomosis worldwide is PJ, 89%, as compared to PG, 10% 
(no or other anastomosis 1%)57. The many different reconstruction techniques 
probably reflect the efforts to minimize anastomotic leakage of amylase, a 
dreaded complication (see below), and the formation of a postoperative 
pancreatic fistula (POPF)1. There are also several modifications within PJ and 
PG, with the same intention. These are end-to-side/end-to-end, duct-to-
mucosa/invagination, one or two-layer anastomosis as well as more advanced 
versions. The current literature regarding differences in leakage is 
Figure 3. Pancreatic reconstructions, a. pancreatojejunostomy (PJ), b. 
pancreatogastrostomy (PG). Reprinted with permission, Ó Corinne Sandone, Johns 
Hopkins University and Ó Anders Flood. 
a b 
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contradictory where non-randomized studies58, 59, randomized controlled 
trials (RCT’s)60-63 and meta-analyses come up with conflicting results64, 65. 
Even if the ISGPS recently summarized that no major difference exists 
between the two reconstructions66 some studies are old, many suffer from 
small study groups and the heterogeneity between even the randomized trials 
is substantial64. A more robust basis for clinical decision-making is needed 
and data from well-structured patient registries, with a larger number of 
patients, could be one way to achieve such knowledge. 
Distal Pancreatectomy 
Tumours in the body and tail are less common than in other locations in the 
pancreas (22-32%)31, 67 and are also to a greater extent unresectable at 
diagnosis, partly due to late onset of symptoms68. If the tumour is found to be 
resectable (no metastases or major engagement of adjacent organs, no 
engagement of the celiac trunk) a distal pancreatectomy (DP) is performed, 
often including a splenectomy en-bloc (Figure 4).  
Figure 4. Distal pancreatectomy and splenectomy with division over the portal vein. 
Reprinted with permission, Ó Corinne Sandone, Johns Hopkins University 
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This procedure leaves no anastomoses. Closing the pancreatic remnant with a 
minimum of POPF development remains a challenge. Since POPF is the most 
common complication after DP and has the potential to severely delay the 
recovery after surgery, several methods to minimize leakage have been 
explored. Examples are absorbable sealant69, 70 or anatomic flap covering the 
stump71, hand-sewn vs. stapled closure of the remnant72, internal stenting of 
the pancreatic duct73, secretion inhibition74 and anastomosis to the stomach or 
the jejunum vs. stump closure75, 76 without significant difference. None of 
these techniques have so far been proven superior regarding the prevention of 
POPF69, 73, 76. However, mesh reinforcement on the stapler line has also been 
tried and has shown a significant reduction in POPF77. This is an interesting 
finding that deserves confirmation, and the design of such a trial became, 
therefore, one aim of the present thesis project (see below).  
Lymphadenectomy 
Because lymphatic metastases are thought to be a tumour-spreading pattern 
that is curable by resection, Lns in the proximity of a cancer are resected en-
bloc at the time of surgery, to improve survival and furthermore to provide 
staging of the disease78, 79. The presence of Ln metastases, postoperatively 
examined, is one of the most important prognostic factors in pancreatic 
cancer67, 80-82. Studies of the lymphatic drainage of the head of the pancreas 
have pointed out primary order nodes; Lns 13 (a and b) and 17 (a and b), that 
drain to second order nodes, Lns 6, 8 (a and p), 12 (a, b and c) and 14 (a, b, c 
and d)79, 83, 84. This has an impact on the pattern of lymphatic metastases and 
prognosis. The Ln-stations that should be resected in a PD or DP have varied 
over time and geographically, where Japan often includes a wider range of 
Ln-stations compared to Europe and Northern America85. The 
recommendation regarding the extent of Ln dissection by ISGPS includes Ln 
numbers 5, 6, 8a, 12b1, b2 and c, 13a and b, 14a and b and 17a and b for PD 
Johanna Hansson Wennerblom 
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and numbers 9 (for tumours in the body of the pancreas) 10, 11d and p, and 
18 in DP11, 86 (Figure 5). But are all regional Ln’s equally important? There 
are studies indicating that some regional Ln’s (e.g. LN 8a) are associated 
with short overall survival87. The clinical relevance of such a survival-
predicting property of the engagement of separate Ln’s has, however, so far 
not been confirmed.  
 
Postoperative management 
Postoperative care after pancreatic surgery varies worldwide. Current trends 
in postoperative care are dominated by ERASÒ (Enhanced Recovery after 
Surgery) protocols and this concept is now applied in several types of cancer 
surgery88. In recent years, interest in similar systematic postoperative care 
after PD has gained ground89. The concept includes, among other things, 
epidural analgesia, early mobilization, use of laxatives, earlier removal of 
nasogastric tube and resumption of oral food intake, most of which are 
already in use but not strictly defined90, 91. Apart from proven benefits to the 
patients in applying ERAS, it may also lead to an update and possibly a 
Figure 5. Japan Pancreas Society nomenclature of peripancreatic lymph nodes and 
the ISGPS recommendation of lymph nodes to resect in a. PD and b. DP. Reprinted 
with permission, Japan Pancreas Society. Classification of pancreatic carcinoma. 
2003. 
a b 
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higher grade of international consensus on what is important in the 
postoperative care of patients with pancreatic resections92.   
Weight gain and elevation in plasma glucose are controlled for and treated, 
since they can negatively affect recovery after surgery93, 94. Output from 
abdominal drains is, if used at all, checked for volume and type of content in 
order to detect signs of leakage from the anastomoses and they are removed if 
no sign of POPF is present on postoperative day three (POD3)91. The need for 
routine abdominal drain is currently the target of a national Swedish study 
randomizing between having a drain or not having a drain after PD. A 
nasogastric tube is often used for the first one to three days and oral feeding 
is then gradually started91.  
Surgical Complications 
Overall postoperative results have improved considerably regarding both 
mortality and morbidity over the last 30 years21. Morbidity, however, still 
remains high with figures from 45-69%21, 95-97. The potentially most harmful 
complication after PD is POPF whereas the most frequent complications are 
delayed gastric emptying (DGE), wound infections and intra-abdominal 
abscesses.  
DGE consists of gastric paralysis without mechanical obstruction, and has 
been defined by ISGPS98. It is an innocuous complication in itself but can be 
a sign of more severe complications99 and markedly affects patient quality of 
life, recovery and length of hospital stay98, 100, 101. It occurs in 14-44%102 21, 100, 
101, 103 after pancreatic surgery. POPF and infections dominate in DP21, 102, 104.   
Specific postpancreatectomy hemorrhage (PPH) is also defined and classified 
by ISGPS105 according to time of onset (early/late), location (intra/extra 
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luminal) and severity. The incidence is 1-10%, the occurrence intimately 
linked to POPF and mortality is high, especially in late hemorrhage106, 107.  
The ISGPS seeks to create a uniform and universally accepted description 
and classification of postpancreatectomy complications (DGE, PPH, and 
POPF) that will facilitate international comparisons of research reports.  
POPF 
This is the potentially most harmful complication after pancreatic surgery and 
deserves some extra attention. It may promote intra-abdominal tissue 
damage, DGE, abdominal abscesses or sepsis and bleeding from central 
abdominal arteries in the region, e.g. the common hepatic artery, as a result. 
This can cause longer hospital stay, increased costs, delayed recovery and 
mortality103, 108. DP was previously considered a minor operation but is now 
recognized as having high morbidity dominated by POPF109, 110. The uniform 
definition of POPF, based on clinical presentation and graded A to C, was 
published by ISGPF (International Study Group for Pancreatic Fistulas) in 
2004 and was revised and updated in 20171, 111 (Figure 6). The incidence of 
clinically relevant POPF (CR-POPF), B and C fistulas, is 12-14% in most 
series97, 112, 113 103. 
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Many risk factors for developing a CR-POPF are reported in the literature108 
and some of the most accepted are non-dilated pancreatic duct and 
soft/normal pancreatic texture103, 112, 113, high body mass index (BMI)114, 
intraoperative blood loss115, long operating time116 and high-risk pathology, 
such as ampullary, duodenal and cystic malignancies110, 112, 113, 115, 116. The 
secretion inhibitor somatostatin (and analogues) has been tested to prevent 
POPF but studies show conflicting results where a Cochrane review 
recommends the use of somatostatin analogues117 and the ISGPF states that it 
may have a role in high-risk patients but not otherwise66. 
Perioperatively discovered unresectable disease  
In patients planned for curative surgery, 8-20% are diagnosed during the 
operation with previously undetected, locally advanced or metastasized 
disease, precluding resection and cure118, 119. With a life expectancy of three 
to 11 months13, 120 it is of major importance to provide the best quality of life 
during patients’ short remaining lifetime. Previous studies have shown that 
• Amylase > 3 times upper limit
• No clinical effect
• Biochemical leak
Grade
A
Grade
B
• Drain > 3 weeks
• Clinical relevant change in management
- Percutaneous/endoscopic drainage
- Interventional radiology for bleeding
- Infection without organ failure
Grade
C
• Reoperation
• Organ failure
• Death
Figure 6. Postoperative pancreatic fistula grading, according to the ISGPF1.  
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75% will develop biliary obstruction and up to 25% will develop gastric 
outlet obstruction (GOO)121, 122 and recommend prophylactic gastric by-pass 
with a concomitant biliary bypass since this procedure prevents recurrent 
obstruction and mortality and morbidity do not increase123, 124(Figure 7). 
 
Critics of this strategy claim that 98% of these patients could be handled 
without surgery125.  Since then we have seen the development of self-
expanding metallic stents (SEMS) and there are studies that indicate similar 
reintervention frequency and number of in-hospital days prior to death, 
Figure 7. Palliative double bypass with hepaticojejunostomy, gastroenteric 
anastomosis and enteroenteric anastomosis. Reprinted with permission,  
Ó Corinne Sandone, Johns Hopkins University 
Common bile duct 
Hepatico- 
jejunostomy 
Jejunum 
Duodenum 
Stomach 
Gastroenteric 
anastomosis 
Enteroenteric 
anastomosis 
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regardless of the initial procedure (surgical bypass or endoscopic stenting)126 
and an indication that prophylactic duodenal bypass does not protect from 
future GOO (Spanheimer-14).  
Palliation by non-surgical techniques is standardized practice when 
unresectable cancer is found during work-up. The double bypass procedure 
has a morbidity and mortality rate of 31–56% and 0–5%, respectively, and 
can decrease the likelihood of receiving systemic treatment123, 124, 126-130. 
Considering that not all patients will develop biliary or gastric obstruction, a 
bypass may even be unnecessary.  
As mentioned before, 75% of pancreatic cancers develop biliary obstruction 
with symptomatic jaundice. Recent studies have shown that biliary SEMS are 
superior to plastic stents regarding dysfunction frequency, complication rate, 
quality of life, patency, need for reintervention and even survival, at the same 
cost131-133. Duodenal SEMS, used in treating patients with advanced disease, 
are today a safe and effective alternative to surgical bypass with at least as 
good quality of life as surgery, and shorter length of stay and time to 
chemotherapy134-137. As of today, no trial exists that directly compares 
endoscopic SEMS for both biliary and duodenal obstruction with 
prophylactic double bypass surgery.  
Oncology 
Adjuvant chemotherapy 
Adjuvant chemotherapy with gemcitabine or fluorouracil, for six months 
after surgery, has a significant survival benefit as compared to no 
chemotherapy (5% vs. 21% five-year survival) in patients resected for 
pancreatic and periampullary cancer138-140. Furthermore, very recently 
published data show the superiority of a combination of gemcitabine and 
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capecitabine, as compared to only gemcitabine, in pancreatic cancer (28.8% 
vs. 16.3% five-year survival) and this treatment is now recommended as first-
line141.  
Palliative chemotherapy 
In reasonably fit patients (ASA classification £2) with pancreatic cancer, 
preferably with locally advanced, and not metastatic, pancreatic and 
periampullary cancer, chemotherapy should be offered after an initial  
discussion in a multidisciplinary board142. In locally advanced pancreatic 
cancer, the addition of chemoradiotherapy or erlotinib to gemcitabine 
treatment has not shown improved survival143, 144. Although in metastatic 
pancreatic cancer several small studies using combination therapy with two 
to three drugs have not shown a better effect145. In 2013, Von Hoff et al. 
showed a 1.8 month longer survival with the addition of nab-paclitaxel, at the 
cost of increased toxicity146. Due to this toxicity and the frailty of patients 
with pancreatic cancer, monotherapy is currently recommended, with 
gemcitabine, fluorouracil or capecitabine, or participation in a clinical drug 
trial 147.  
Prognosis 
There are several tools to prognosticate in cancer disease and for solid 
tumours the TNM staging system, developed and maintained by The Union 
for International Cancer Control (UICC), is one of the most frequently 
used148. It relies on anatomical extent of the tumour growth, where T stands 
for size of the tumour, N describes spread to regional lymph Nodes and M 
stands for distant metastases. These three (TNM) put together give a stage 
that correlates to prognosis. 
In pancreatic cancer, even among patients who undergo tumour resection, 
recurrence rates are high and long-term survival is scarce. Why is this? There 
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are studies on mutations in pancreatic cancers, using mathematical models, 
showing that the development of a cancer takes ten to 20 years to develop 
from the initiation of tumorigenesis in a cell into a metastatic cancer149. In 
this model the vast majority of patients are diagnosed in the phase where the 
tumour cells have acquired the ability to metastasize. Various tumour-related 
factors have been identified as predictors of survival, in addition to the TNM 
system, after potentially curative resection. These factors include tumour 
size, lymph node disease, tumour grade and vascular invasion150. 
On diagnosis, 50-60% have distant metastases, up to a third have borderline 
resectable or locally advanced disease (some resectable with neoadjuvant 
treatment and some not) and 15-20% are potentially curable151-153. For the 
entire group, including non-resectable stages, the five-year survival is 6-8% 
and the median survival 25 months31, 154 whereas the median survival in 
locally advanced cancer is six to 11 months and in metastatic disease three to 
six months13, 120. After surgery and adjuvant chemotherapy, the five-year 
survival is 14-26%8, 9, 11, 155, the median survival time is 14-22 months12-14 
and, looking at the subgroups of periampullary cancer, extrahepatic bileduct 
cancer has a five-year survival of 25% and a median survival of 29 months11, 
21 ampullary cancer 44-48% and 29-36 months11, 14 and duodenal cancer 48-
73% five-year survival11, 21.  
There are several known prognostic factors of survival where some of the 
most important are age156, tumour stage156, tumour size157, 158, resection 
margins11, 156, number of metastatic Lns67, 159, 160 and Ln ratio (metastatic/total 
number Lns resected)11, 156. These factors are not accessible preoperatively 
and can therefore not be used in treatment decision-making. Interest has been 
drawn to the location of Ln metastasis and its impact on prognosis. Extended 
Ln resection, including para-aortic Lns, has not conveyed prolonged survival 
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but possibly increased morbidity11, 85, 161, 162. Metastases to second-order Lns 
are associated with decreased survival67, 80, 87, 163. However, metastatic Lns are 
not readily identified on radiologic imaging and they are not always obvious 
during surgical dissection85. A useful prognostic factor would be one that is 
assessable before resection, e.g. via diagnostic laparoscopy, when it can be 
included in staging and the planning of treatment modality.   
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2 Aims 
As mentioned above, there are several knowledge gaps in the field of surgical 
treatment of pancreatic tumours, and this thesis project focuses on some of 
them. The overall aim was to investigate whether modification of existing 
surgical techniques and routines can improve postoperative outcome in 
patients.  
The specific aims were 
• to evaluate whether prophylactic surgical double bypass or 
endoscopic treatment on demand, with stents, is better for 
patients with perioperatively unresectable periampullary 
cancer. 
• to investigate whether tumour involvement of the regional 
lymph node 8a is of prognostic importance for overall 
survival in patients operated with PD for suspected 
pancreatic and periampullary cancer. 
• to analyse whether a biodegradable reinforcement material, 
of the stapler line on the pancreatic stump after distal 
pancreatectomy, can reduce the frequency of postoperative 
pancreatic fistulas.  
• to assess whether pancreatogastric anastomosis reduces the 
postoperative pancreatic fistula rate, after 
pancreatoduodenectomy, as compared to pancreatojejunal 
anastomosis. 
 
Johanna Hansson Wennerblom 
21 
3 Methodological considerations 
3.1 Common definitions and tools 
Postoperative complications are graded according to the Clavien Dindo 
classification164 where the therapy used to correct a specific complication 
defines the severity of the complication. The highest rank scored is the one 
used on a five-grade scale (I-V). This was registered 30 days postoperatively 
or at discharge. 
The ISGPF classifications of POPF1, 111 and the ISGPS classification of 
DGE98 were used in papers I, III and IV. 
Ln stations were resected, in PD and DP, as defined by the ISGPS and the 
JPS11, 86, 165. 
Postoperative day 1 (POD1) was the first day after surgery.  
Postoperative length of stay (LOS) was the total number of in-hospital days 
after the operation. 
Mortality was specified as in-hospital or within 30 days of surgery in papers 
I, III and IV. 
In paper II, deaths were recorded until the last day of follow-up (³five years). 
Collection of data on demographics, histopathology and peri- and 
postoperative outcome was made from medical records and surgical planning 
software at the hospitals involved, as described below.  
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3.2 Paper I 
To answer the question in the study reported in Paper I an RCT was started, 
but it turned out to be difficult to include patients. Thus the study was halted 
and we searched for an alternative approach. At Sahlgrenska University 
Hospital, unresectable disease found during surgery was treated with 
prophylactic double bypass (DoB), hepaticojejunostomy and 
gastroenterostomy. At Skåne University Hospital, Lund, symptomatic biliary 
obstruction and/or gastric outlet syndrome (GOO), at the time of surgery, 
were treated with surgery or endoscopy (with SEMS). Non-symptomatic 
patients were observed and treated when they exhibited symptoms of biliary 
obstruction or GOO (Wait-and-See, WaS). This presented us with the 
alternative of a retrospective cohort study in seeking an answer to the 
question of which treatment strategy was best for these patients. With this 
study design, however, causality can not be demonstrated and there is risk of 
bias, such as missing data or patients lost to follow-up, and confounding, e.g. 
differences in the demographics of the two groups. The two study groups 
were also from two different hospitals, potentially adding to difficulties 
comparing the groups. To minimize this the authors decided on definitions 
for the different study parameters in a consensus meeting and two of the 
authors then collected the data from hospitals in the Västra Götaland Region 
and Region Skåne, one at each hospital. 
All patients with interrupted PD, because of locally advanced or metastasized 
disease, at Sahlgrenska University Hospital and Skåne University Hospital, 
Lund, between 2004 and 2013, were included. Benign disease and endocrine 
cancers were excluded. Patients at the two hospitals were compared regarding 
complications, short and long-term postoperative outcome, including re-
interventions and re-admissions due to biliary obstruction and/or GOO, 
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Enrollment
Allocation
Assessed for eligibility (n= 122)
Excluded  (n= 35)
• Advanced malignancy, no resection (n= 13)
• LN8a not resected separately (n= 19)
• Other operation than PD (n=2)
• Non radical operation (n=1)
Ln8a positive (n=16)
• Pancreatic and periampullary cancer (n=14)
• Neuroendocrine cancer (n=2)
Ln8a negative (n=71)
• Pancreatic and periampullary cancer (n=52)
• Neuroendocrine tumour (n=1)
• Premalignant lesion (n=11)
• Benign lesion (n=5)
• Pseudopapillary tumour (n=1)
length of stay and overall survival. The groups were analysed with Intention 
to Treat (ITT). Endpoints were complications and long-term follow-up. 
The differences between the groups were discussed so that the potential effect 
of this on outcome would at least not lead to an overestimation of results. 
Regarding the comparison of the two hospitals, no differences in 
postoperative treatment and outcome have been shown between the two in 
the yearly reports from the Swedish National Pancreatic and Periampullary 
Cancer Registry (SNPPCR)166. 
3.3 Paper II  
 
In this study we used a prospective cohort study design including patients 
operated with PD between 2008 and 2011 at Sahlgrenska University 
Hospital, see the flow chart (Figure 8). Only patients operated with suspicion 
of malignant disease were included. 
Figure 8. Flow chart on patients in paper II. Ln, lymph node; PD, pancreatoduodenectomy. 
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A standard PD was performed but Ln8a was resected and sent as a separate 
specimen to the Pathology Department, where it was stained according to 
routine (haematoxylin and eosin) to find metastases and analysed with 
immunohistochemistry to detect micro-metastases. The two groups were 
defined by tumour status in Ln8a, noted as + or – for tumour growth, and 
compared. A survival analysis was performed comparing the two groups. The 
adenocarcinomas were then analysed separately, looking for independent 
predictors of short survival, with uni and multivariate analysis. 
The primary endpoint was overall survival (OS) according to the tumour 
status of Ln8a. 
Since the exposure is relatively uncommon (Ln8a+) we both had few 
numbers and skewed group sizes to work with. We used statistical methods 
allowing for this and the outcome of the study is clearly significant. To check 
for bias with regard to the excluded group, their demographics were analysed 
and were not found to differ from the study group. 
3.4 Paper III 
A multicentre RCT design was used, randomizing patients planned for DP 
from 2014 to 2016 to stapler division of the pancreas with or without a 
biodegradable reinforcement material (Biodesign® Staple Line 
Reinforcement, COOK® Medical). A power calculation was made on a 
previously observed POPF frequency of 25% and an expected reduction of 
20% of the POPF rate in the intervention group. To detect this, 100 patients, 
50 in each arm, were needed (Figure 9). The randomization was carried out 
using opaque envelops in bundles of ten at each centre, drawn at the time of 
surgery when resection was deemed feasible. There was no systematic 
blinding, as it was not deemed to interfere with study outcome. 
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Enrollment
Allocation
Analysis
Follow-Up
Assessed for eligibility (n=145)
Excluded (n=38)
• Non resectable malignancy (n=8)
• Not operable patient (n=1)
• Declined to participate (n=1)
• Other operation performed (n=13)
• Not included, reason unknown (n=15)
Analyzed (n=54)
• Excluded from analysis (n=0)
Lost to follow-up (n=0)
Reinforced stapling (n=56)
• Received allocated intervention (n=54)
• Did not receive allocated intervention (n=2)
- technical problems perioperatively
Lost to follow-up (n=0)
Conventional stapling (n=51)
• Received allocated intervention (n=51)
Analyzed (n=50)
• Excluded from analysis (n=1)
- death POD2 cardiac arrest
Randomized (n=107)
Reason for resection, operative technique used (open/laparoscopic), 
splenectomy or not and the use of prophylactic Somatostatin did not interfere 
with the study protocol but were registered. All patients were followed until 
drain removal. 
Sahlgrenska University Hospital, Karolinska University Hospital at 
Huddinge, Skåne University Hospital at Lund and Linköping University 
Hospital participated in the study. Fistulae were diagnosed and graded 
according to the ISGPF classification of 2004111. Day of drain removal, LOS, 
re-interventions and re-admissions were recorded. The stapler-only group and 
the group with reinforcement on the stapler-line were compared. 
Figure 9. Flow chart on patients in paper III. POD2, postoperative day 2. 
Johanna Hansson Wennerblom 
26 
 
The primary endpoint was the development of a POPF and secondary 
endpoints were morbidity, mortality and LOS. 
 
One possible weakness worth mentioning is that in this study the pancreatic 
texture and duct width were not registered in this study and since these 
characteristics are known risk factors of POPF, this may have introduced a 
selection bias. Patients of all ages, all diagnoses and any operative approach 
(open or laparoscopic) were included, rendering external validity to the data. 
3.5 Paper IV 
This study was registry based using prospectively gathered data from the 
SNPPCR. The study included patients operated with PD and reconstructed 
with either PG or PJ between 2010 and 2016. Pylorus preserving PDs (PPPD) 
were not included, in order to achieve a more homogenous study group. The 
reason for resection was noted but did not interfere with the study protocol. 
The material was divided and compared with regard to the two different 
pancreatic reconstructions, PG and PJ. Parameters used to assess POPF were 
pancreatic leakage, drain amylase on POD3, postoperative bleeding, DGE 
and re-operation. 
The primary endpoint was the development of a CR-POPF and secondary 
endpoints were other complications and their severity grade, according to the 
Clavien Dindo classification, and LOS. 
Data collection was restricted to parameters included in the registry, and 
there is a risk of information bias both regarding missing data and how 
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parameters are interpreted when registered. In Paper IV some of the 
demographic differences between the groups, such as ASA classification and 
the frequency of preoperative biliary drainage, are believed to stem from 
regional interpretational differences and traditions, respectively. We have 
within the frame of this study not been able to address the characteristics of 
the missing group, potentially introducing a bias, but the extent of missing 
data in this material ranges from 0.1 to 10.1%. Some parameters, often used 
in the study of pancreatic complications, such as pancreatic consistency and 
pancreatic duct width, are unfortunately not included in the registry, and not 
stratifying for this can possibly have introduced a bias. The coverage of the 
registry is 85-99% (forms A-D) and the coverage rate of malignant patients 
for the time period, as compared to the national Swedish cancer registry, is 
86%. For these reasons validity is judged to be good. 
3.5.1 Swedish National Pancreatic and Periampullary 
Cancer Registry 
The Swedish National Pancreatic and Periampullary Cancer Registry 
(SNPPCR) contains data concerning treatment of patients with pancreatic and 
periampullary tumours.  
From 2010, data on patients are prospectively registered and in 2015 and 
2016 the Registry was validated and showed good results. For resected 
patients, the parameter coverage is more than 85%, making it possible to 
draw conclusions on trends over regions and time31.  
3.6 Statistics 
Power calculations are made with a two-sided a-level of 5% and a power of 
80%. 
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Continuous data are presented as mean, median and range or IQR and 
categorical variables as numbers/frequencies and percentages, as appropriate. 
For comparison between two groups, the Mann–Whitney U-test was used for 
continuous variables and the Chi-square, Fisher exact and Mantel Haenszel 
Chi-square tests for dichotomous variables. All significance tests were two-
sided and conducted at the 5% significance level. 
Survival analysis was made using Kaplan Meier curves (papers I and II). 
Univariate analysis was made using the Log-rank test for dichotomous 
variables. Hazard ratios were calculated with Cox proportional hazards 
regression model. Multivariate Cox analysis was performed to find 
independent predictors of OS (paper II). 
In paper IV an adjusted analysis was made, using logistic multivariate 
regression, for factors potentially influencing fistula formation, apart from 
PG/PJ. 
Statistics software: SAS System Version 9, Cary, NC, USA and SPSS 
statistical package, v22.0-24.0, SPSS Inc.®, Chicago, Ill 
3.7 Ethical considerations 
All study protocols were approved by the Regional Medical Ethics 
Committee, papers I, II and IV by the Committee in Gothenburg and paper III 
by the Committee in Stockholm. 
In paper III, patients were provided with verbal and written information 
regarding the study and intended intervention prior to giving their written 
consent for participation and the study was registered on clinicaltrials.gov 
(NCT02149446). 
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4 Summary of Results 
4.1 I. What to do when unresectability is discovered 
peroperatively? 
This retrospective cohort study included 143 patients, 73 from Sahlgrenska 
University Hospital constituting the DoB group and 70 from Skåne 
University Hospital Lund constituting the WaS group.  
The WaS group was significantly older (70 vs. 66 years, p=0.013) and had a 
significantly higher ASA score (p=0.049). The two groups were comparable 
regarding tumour characteristics: histopathology, tumour size and stage, 
reason for non-curative surgery, and postoperative palliative chemotherapy 
(60-64%). The DoB group had a significantly higher blood loss (600 ml 
(100–5000) vs. 200 ml (0–900), p < 0.001) and a need for blood transfusion 
(32% vs. 14%, p = 0.017) than the WaS group, but operation duration did not 
differ. Reconstructions performed and postoperative outcome are presented in 
Table 2. 
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Table 2. Initial procedure and postoperative outcome. WaS, wait and see; DoB, 
double bypass; DGE, delayed gastric emptying. n (% / range) 
 
WaS  
(n=70) 
DoB 
(n=73) 
p-value 
Operative procedure    
  DoB 12 (17) 59 (81)  
  Hepaticojejunostomy 0 12 (16)  
  Gastroenterostomy 10 (14) 2 (3)  
  WaS 48 (69) 0  
Postop. Complications 22 (31) 48 (67) < 0.001 
DGE 12 (17) 26 (36) 0.017 
Clavien Dindo IIIa - V 3 (4) 17 (23) 0.001 
Primary length of stay 8 (2-36) 14 (6-71) 0.001 
 
The significant difference in DGE probably influences the difference in the 
Clavien Dindo score and LOS.  
When followed over time, the two study groups had the same requirement of 
re-admission for biliary or gastric outlet obstruction (WaS 61% vs. DoB 
67%, p=0.491) but, when adding up the total hospital stay (primary and 
subsequent), the difference in LOS remained (18 days (3–74) for WaS vs. 24 
days (8–53) in the DoB group, p = 0.001). The stented group was separated 
in the analysis of bile duct related complications according to stent material, 
plastic or SEMS, revealing a greater need for in-hospital care in the plastic 
stent group and equal outcome for SEMS vs. DoB (Table 3). 
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Table 3. Outcome regarding hospital stay and re-interventions due to biliary 
complications. ERC, endoscopic retrograde cholangiography; PTC, percutaneous 
transhepatic cholangiography; SEMS, self-expanding metal stent. n (% / range).  
 
When looking at morbidity related to gastric outlet obstruction (GOO), the 
WaS group and the DoB group developed GOO to a similar extent and 
needed in-hospital care and re-intervention for GOO to a similar extent, 
meaning that DoB did not prevent GOO (Table 4). 
Table 4.  Outcome regarding Gastric outlet obstruction. n (% / range).  
 
 
WaS plastic 
(n=25) 
WaS SEMS 
(n=23) 
DoB 
(n=73) 
p-value 
Readmission due to 
cholangitis/cholestasis 
 
17 (68) 6 (26) 11 (15) 0.001 
Hospital stay due to 
biliary problems 
 
10 (0-36) 4 (0-27) 4 (0-42) 0.001 
ERC/PTC after initial 
intervention 
37 13 10 0.001 
 
WaS  
(n=70) 
DoB  
(n=73) 
p-value 
Gastric outlet obstruction  13 (18) 9 (12) 0.350 
Endoscopic stent 7 (10) 5 (7) 0.550 
Surgical bypass 6 (8) 1 (1) 0.060 
Hospital stay due to 
Gastric outlet obstruction 
15 (8-46) 17 (7-92) 0.473 
Johanna Hansson Wennerblom 
32 
In conclusion, DoB is associated with higher postoperative morbidity and 
longer in-hospital stay as compared to the WaS strategy.  The results thus 
support the use of the latter strategy.  
4.2 II. Can lymph node 8a predict advanced 
disease? 
A prospective protocol was applied from 2008 to 2011. During the study 
period, 122 patients were eligible for separate assessment of Ln8a. Thirty-
five patients were excluded, as presented in the flow chart (Figure Y). The 
study groups consisted of 16 patients with metastatic growth in Ln8a (Ln8a+) 
and 71 patients with a normal Ln8a (Ln8a-).  
The immunohistochemistry revealed another three metastatic Lns except for 
the 13 found on routine staining, and the origin of the cancer could also be 
diagnosed in the Ln analysis (adenocarcinoma or neuroendocrine cancer). 
There were no significant differences in demography between the groups 
(age, gender, ASA score) even when only the subgroup of adenocarcinomas 
was considered (14 vs. 52 patients) and they received adjuvant chemotherapy 
to the same extent. The median follow-up was 6.7 (5.3-8.2) years or until the 
time of death.  
In the survival analysis, there was a significant difference between the Ln8a+ 
and the Ln8a- groups (0.74 years (95% CI 0.26–1.26) versus 5.91 years (95% 
CI 2.91–), p< .001), shown in Figure 10. The one long-time survivor in the 
Ln8a+ group had an endocrine tumour. When comparing only 
adenocarcinomas, there was still a significant difference (0.74 years (95% CI 
0.23–1.26) versus 2.93 years (95% CI 2.00–), respectively, p< .001) and, 
when further comparing Ln8a+ adenocarcinomas with Ln8a- but Ln+ 
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adenocarcinomas (standard Ln stations), there was also a significant 
difference. 
The OS in the Ln8a+ group resembled that of unresectable disease; 8.3 
months in our material and three to 11 months in the literature13, 120. 
Furthermore, the uni- and multivariate analyses of the adenocarcinomas, 
searching for independent predictors of short OS, showed that Ln8a+ is an 
independent predictor. 
Taken together, the results confirm previously published results from Connor 
et al.87, that tumour involvement in Ln8a is associated with significantly 
reduced overall survival.  
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Figure 10. Kaplan Meier curve on overall survival in Ln8a+ and Ln8a- patients. Ln, 
lymph node. 
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4.3 III. Does mesh reinforcement of the pancreatic 
stump, after distal pancreatectomy, reduce 
fistula formation? 
To address the question we adopted an RCT design involving four centres. 
During the study period, 145 patients were eligible, of which 38 were 
excluded, for different reasons (Figure Z: flow chart) and 107 randomized, 
resulting in an intervention group of 56 patients and a control group of 51 
patients. In the intervention group, two patients did not receive the allocated 
treatment, reinforcement on the stapler line, because of technical problems 
during the operation, and one patient in the stapler-only group died on POD2 
from myocardial infarction, before assessment of POPF was possible, and 
was excluded from final analysis.  The study group consisted of 104 patients 
(71.7%), 54 patients allocated to stapling with reinforcement (51.9%) and 50 
patients allocated to stapler division only (48.1%). The groups were 
comparable regarding demography (BMI, ASA score etc.) previous 
abdominal surgery, use of prophylactic somatostatin and final histopathology.  
Table 5. Operative data, paper III. n (% / range) 
  
 
Stapling with 
reinforcement  
(n=54) 
Stapling 
(n=50) 
p-value 
Type of operation   0.795 
  Open 43 (80) 41 (82)  
  Laparoscopic 11 (20) 9 (18)  
Duration of operation 150 (64-400) 152 (54-327) 0.795 
Splenectomy 14 (26) 16 (32) 0.495 
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The two groups were also equal in perioperative outcome such as surgical 
approach (laparoscopic/open), multivisceral resection, operation duration and 
perioperative blood loss (Table 5). The development of POPF did not differ 
between the two groups, nor did development of CR-POPF. The overall 
morbidity (79%) in the study group was quite high but severe complications 
(Clavien Dindo IIIb-V) were uncommon and no grade IV or grade V 
morbidity was registered in either group (Table 6).  
In accordance with already mentioned results, there was no difference 
regarding different major surgical complications (bleeding, DGE, abdominal 
fluid collections) or time to drain removal. Nor were there any differences in 
LOS, re-admission or re-intervention rate. 
Table 6. Postoperative outcome, paper III. POPF, postoperative pancreatic fistula.  
n (% / range) 
  
 
Stapling with 
reinforcement  
(n=54) 
Stapling 
(n=50) 
p-value 
Grade of POPF   0.980 
  0 32 (59) 21 (42)  
  A 16 (30) 21 (42)  
  B + C 6 (11) 8 (16)  
Clavien Dindo   0.627 
  0 32 (59) 21 (42)  
  I – IIIa 46 (85) 40 (80)  
  IIIb - V 2 (4) 4 (8)  
Length of stay 9 (2-35) 9 (2-114) 0.695 
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In conclusion, our results showed no difference in fistula rates. In other 
words stump reinforcement does not appear to convey an outcome advantage. 
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4.4 IV. Does choice of reconstruction influence 
fistula formation following 
pancreatoduodenectomy?  
Data were collected from the SNPPCR. During the study period, from 2010 
to 2016, a total of 2051 PDs with a pancreatic reconstruction (PG or PJ) were 
registered. Of those 36 (1.8%) were miscoded and had to be omitted. Pylorus 
preserving PDs (PPPD) were not included leading to the exclusion of another 
330 operations (16.1%). This resulted in a study group of 1685 patients 
(82.2%), 567 with PG reconstruction (33.6%) and 1118 with a PJ 
reconstruction (66.4%).  
The groups were comparable regarding age, gender, BMI and comorbidity. 
The ASA score was higher in the PJ group (p<0.001). Preoperative biliary 
drainage and prophylactic use of Somatostatin were more frequent in the PG 
group compared to the PJ group (69.5% vs. 61.4%, p<0.001; 70.1% vs. 
29.2%, p<0.001, respectively). Histopathology, metastatic Lns and tumour 
stage were comparable in the two groups with the exception of the total 
number of Lns resected, where PG had a median of 18 (0-54) and PJ a 
median of 21 (0-99) resected. Operation time was significantly longer for PG, 
with a median of 410 (183-840) min, compared to PJ, 373 (96-820, p<0.001) 
min, and a lower frequency of venous resections (13.1% vs. 22.0%, p<0.001). 
The group differences were considered not to affect the results and will be 
further discussed in the general discussion below. 
The postoperative outcome showed a significantly lower rate of POPF after 
PG compared to PJ (18.1% vs. 28.5%, p<0.001) as well as rate of CR-POPF 
(fistulas grade B and C) (11.1% vs. 19.8%, p<0.001), presented in Table 7. 
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Table 7. Postoperative outcome, paper IV. PG, pancreatogastrostomy; PJ, 
pancreatojejunostomy, CR-POPF, clinically relevant postoperative pancreatic 
fistula; DGE, delayed gastric emptying. n (%). 
 
PG  
(n=567) 
PJ 
(n=1118) 
p-value 
Surgical complications 237 (43.0) 586 (56.7) <0.001 
  Wound infection 69 (12.5) 65 (6.3) <0.001 
  Intraabdominal abscess 52 (9.4) 117 (11.3) 0.27 
  CR-POPF  61 (11.1) 205 (19.8) <0.001 
  DGE 76 (13.8) 258 (25.0) <0.001 
  Bile leakage 22 (4.0) 53 (5.1) 0.38 
  Postoperative bleeding 37 (6.7) 109 (10.5) 0.014 
  Wound dehiscence 16 (2.9) 41 (4.0) 0.32 
  Other 26 (4.6) 148 (13.2) <0.001 
Re-operation 46 (8.3) 127 (12.3) 0.018 
Clavien Dindo   <0.001 
  0 270 (49.0)  369 (35.7)  
  I - IIIa 223 (40.5) 403 (48.6)  
  IIIb - V 58 (10.5) 162 (15.7)  
Mortality 7 (1.3) 25 (2.4) 0.14 
 
Postoperative bleeding, DGE and reoperations were also less frequent in the 
PG group whereas wound infections were more common in PG. Mortality 
was comparable in the two groups, 1.3% vs. 2.4%, p=0.14. 
In addition to anastomotic technique two other parameters had significantly 
lower POPF rates, biliary drainage and use of somatostatin. An analysis, 
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using logistic multivariate regression, was performed to evaluate the effect 
that the pancreatic anastomosis (PG and PJ) had on fistula development when 
adjusting for biliary drainage and somatostatin use. The result remained 
significant meaning that type of anastomosis still had a significant effect on 
POPF development.  
On the basis of these results, it appears that pancreatogastrostomy is a safer 
reconstruction after pancreatoduodenectomy.  
Johanna Hansson Wennerblom 
40 
5 Conclusions  
• Patients with unresectable periampullary cancer at 
laparotomy, without obstructive symptoms can safely be 
managed endoscopically, with metallic stents, on demand. 
This strategy has significantly lower morbidity and shorter 
length of hospital stay compared to prophylactic surgical 
double bypass. Prophylactic duodenal bypass does not 
prevent future gastric outlet obstruction. 
 
• Tumour involvement of lymph node 8a, in suspected 
pancreatic or periampullary carcinoma, is associated with 
significantly reduced overall survival, indicating a possible 
role in the preoperative workup ahead in these patients.  
 
• Reinforcement with a biodegradable mesh in the stapler 
closure of the pancreatic remnant, in distal pancreatectomy, 
does not decrease the rate of overall or clinically relevant 
pancreatic fistulas. 
 
• Pancreatogastrostomy appears to be a safer pancreatic 
reconstruction than pancreatojejunostomy, after 
pancreatoduodenectomy, due to significantly less risk of 
developing clinically relevant pancreatic fistulas. 
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6 General discussion  
6.1 Surgery in a palliative setting (Paper I) 
 
A majority of patients with pancreatic cancer are beyond cure at diagnosis 
but, with a fairly good performance status, they can have prolonged survival 
with palliative chemotherapy. In spite of the current work-up for pancreatic 
cancer, with high quality imaging, patients are still found to have 
unresectable disease at surgery with curative intent, due to metastatic or 
locally advanced disease. These patients have an aggressive tumour and short 
life expectancy. The tumour is prone to obstruct the biliary outflow and the 
duodenum as it progresses. Optimal palliative treatment is of the utmost 
importance, including maintaining biliary and intestinal patency and 
providing prompt chemotherapy.  
It has previously been shown that double bypass surgery, performed at initial 
laparotomy, is a safe and effective treatment in avoiding future obstruction123, 
124. But this means preventing obstruction in 20% of the patients and an 
unnecessary operation in 80% of patients. Data from other studies say that 
non-curative surgery is associated with high morbidity, potential mortality 
and a patency of surgical bypasses that does not exceed endoscopic SEMS 
alternatives122, 126-128. It may also lead to less chemotherapy and shorter 
survival128, 167. SEMS is already the treatment of choice in patients with 
known palliative disease168. 
Results reported in paper I show that the DoB group resumed oral feeding 
later, had twice as many complications and longer hospital stay compared to 
the WaS group. During the study period, there was a shift from plastic stents 
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to SEMS in our material, in analogy with results from others demonstrating 
improved patency for SEMS169. When comparing biliary complications in our 
study, the group with SEMS (subgroup in WaS) and the DoB group had an 
equal frequency of re-admissions and re-interventions, suggesting that DoB 
does not protect from future hospitalization, as shown by others126. In this 
paper, plastic stents were inferior to both metallic stents and surgical bypass 
with respect to re-interventions and re-admissions. 
Regarding GOO related complications, the DoB group was in similar need of 
re-admission and re-intervention as the WaS group, indicating that DoB does 
not protect from future GOO, parallel to results presented by Spanheimer128. 
Paper I supports a current strategy of only treating symptomatic patients and 
when doing so using metal stents as the primary strategy, saving surgery for 
cases not suitable for endoscopy. 
6.2 Looking for a diagnostic tool (Paper II) 
The potential cure for patients with pancreatic and periampullary cancer is 
PD, which is a major operation with a recovery of several months. In patients 
with early tumour recurrence (<12 months) after a PD, which is correlated to 
a poor prognosis170, there is a risk of not benefiting from the resection and of 
not receiving chemotherapy. This group would perhaps have had better effect 
of chemotherapy from the start. In a retrospective study, Connor et al. found 
that tumour involvement of Ln8a was a predictor of short overall survival in 
patients resected for pancreatic cancer87. This Ln station is accessible without 
major dissection or adding surgical trauma to the patient, presenting it as a 
possible staging tool. 
In our prospective cohort (paper II) we show that metastasis to Ln8a is 
associated with a significantly shorter OS compared to patients with tumour 
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free Ln8a, regardless of tumour engagement of other regional Lns. Other 
studies on this subject also present a short OS whereas some do not find a 
difference between Ln8a engagement and Ln engagement overall87, 171, 172.  
The Ln8a+ patients and the unresectable patients, not included in the study, 
had a similar survival time in both our and Connor’s data87. Others have seen 
a shorter OS but still longer than without surgery, for which reason they still 
propose resection for these patients173. 
Both routine staining and immunohistochemistry were used to detect 
metastases, resulting in three patients diagnosed only with the latter method. 
The relevance of detecting metastases with immunohistochemistry has been 
previously demonstrated by Bogoevski et al. who also found metastatic 
engagement of Ln8 (common hepatic artery in their study) to be a prognostic 
factor of short OS174. 
In our Ln8a+ group there were 14 adenocarcinomas and 2 neuroendocrine 
cancers and the different diagnoses could be made from the Ln8a specimen, 
making it even more useful as a potential prognostic tool.   
We have included all patients where pancreatic or periampullary cancer 
cannot be ruled out preoperatively, regardless of what postoperative 
diagnosis they had. This mirrors the clinical situation we are faced with and 
for which we need a prognostic tool. Other studies only present 
adenocarcinomas87, 171-173, 175 and in our subgroup analysis, only 
adenocarcinomas, OS is still significantly shorter in the Ln8a+ group. 
Paper II shows that Ln8a is a strong predictive factor of reduced OS. This 
could perhaps play a role in characterizing tumours in the pancreatic and 
periampullary region preoperatively, e.g. by resecting the node during 
diagnostic laparoscopy. 
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6.3 Operative technique in pancreatic surgery 
As described above the problem with a high burden of complications, 
potentially of a severe character, accompanies pancreatic surgery and so do 
efforts to improve outcome. An important parameter in post pancreatectomy 
complications is the formation of POPF, caused by leakage from the 
pancreatic anastomosis (in PD) or the divided pancreatic stump (in DP), 
which can lead to further complications. Hence much effort has been devoted 
to optimizing the pancreatic anastomosis and division techniques. 
6.3.1 Minimizing POPF in Distal Pancreatectomy (paper 
III) 
Numerous methods have been tested to minimize POPF formation after DP, 
as described above, but very few have shown significant differences. 
Promising results presented from a study using prosthetic mesh 
reinforcement of the stapler line showed a POPF frequency of 1.9% in the 
reinforcement group as compared to 20% in the non-reinforced group.  
In paper III we investigate whether this effect would hold for a biodegradable 
reinforcement, considering potential complications related to prosthetic 
material. We could however not show any difference in POPF frequency 
between the reinforced and the non-reinforced group, neither for overall 
POPF nor for CR-POPF. And there was no difference in any of the 
postoperative outcome parameters. These results are concurrent with findings 
of others, trying different techniques at the stump of the pancreas69, 72, 74, 75, 109, 
even if there are exceptions77, 176. We can currently not recommend the use of 
reinforcement on the stapler in DP. 
The reason for the low success rate of different surgical techniques in 
decreasing POPF frequency is still unknown but, from described experiences, 
it is possible that the answer lies elsewhere. There are studies indicative of 
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pancreatitis and ischemia, combined with intrinsic characteristics of the 
gland, being mechanisms behind the development of POPF, triggered by the 
trauma the surgery inflicts on the pancreas103, 177, 178. 
6.3.2 Minimizing POPF in pancreatoduodenectomy (paper 
IV) 
In paper IV, comparison of the two most common anastomotic techniques, 
PG and PJ, shows that PJ has significantly more CR-POPF and a higher 
overall morbidity. Others have found PJ to be associated with higher POPF 
frequency62, 179, 180, but there are also studies showing no difference61, 63, 181 or 
the opposite182.  
Furthermore, the PJ group had more post pancreatectomy hemorrhage (PPH), 
more often DGE and more re-operations. This is not surprising and most 
likely a consequence of the higher frequency of POPF after PJ. In contrast, 
several studies with a significant difference in POPF, often in favour of PG, 
do not show a difference in morbidity or mortality183-185. This may be 
explained by inclusion of all POPF, not only CR-POPF. 
In analogy with the above one would expect a longer hospital stay in the PJ 
group, which we did not show. There are however data showing that 
significantly more PJ patients were discharged to another hospital ward 
compared to PG patients, who were significantly more often discharged to 
the home.  
The use of Somatostatin to prevent POPF is much debated. No international 
consensus has been reached117, 186 and there are consequently no 
recommendations. The present study showed that Somatostatin was used 
significantly more often in the PG group, possibly affecting fistula formation. 
However, when adjusted for in the regression analysis, it did not affect 
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POPF.  Since the effect of Somatostatin in POPF development is not 
universally agreed upon, it has been suggested that it be regulated in future 
RCTs minimizing heterogeneity64. 
Our two study groups differ regarding preoperative biliary drainage, possibly 
reflecting different local regimens in the treatment of jaundice. The parameter 
was adjusted for in the regression analysis and did not interfere with the 
effect that anastomosis had on POPF development. However it still remained 
significant indicating a role in fistula formation.  
The differences seen in ASA classification and perioperative blood loss 
between the groups are difficult to explain but may stem from differences in 
interpretations of parameter definitions: in the former, and absence of a 
standardized method of measurement, in the latter, when filling in the registry 
forms. Low correlations in some registry parameters were observed in the 
validation of the Registry, performed in 2015 to 2016, which overall showed 
good results (submitted manuscript). Over the years, continuous work has 
been done in, from the Registry Steering Committee to harmonize 
interpretations of parameters and simplify registry forms in order to improve 
the quality of data, which can be seen in the yearly reports from the 
Registry31. The work of further developing the registry must however go on.  
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7 Future perspectives 
The majority of the papers in this thesis is the result of Swedish 
collaborations; paper I, III, IV. They have come about thanks to years of 
work with founding and developing the Swedish National Pancreatic and 
Periampullary Registry and the Swedish Study Group for Pancreatic Cancer. 
The nearby future lies in continuing and expanding these collaborations in 
order to generate ideas and increase population size. 
We have come a long way in optimizing perioperative care in order to 
minimize postoperative complications and this will continue not only through 
registry data and collaborations but also with the help of data from the 
ERASÒ database. 
In spite of results described above and throughout this thesis fistula 
frequency is still, at best, 11% telling us that the answer must lie elsewhere. 
Further research on fistula formation should address questions of 
inflammation and ischemia caused by the surgical trauma and inherent 
properties of the pancreatic tissue predisposing of pancreatic leakage.   
Furthermore the vast majority of our patients will be faced with recurrent 
disease, in spite of curative surgery. And we are still faced with the large 
group of patients that have a disease beyond cure from the start. This implies 
a need for shift of focus. Further development of surgical techniques will not 
be the solution for our patients. The next step must be the development of 
systemic treatments for this systemic disease. Surgery will be an important 
part of the treatment but whom to take to surgery and when will maybe 
change in a new chemotherapy era. And this future also demands national 
and international collaborations, with surgeons, oncologists as well as 
radiologists. 
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Errata 
Paper II 
Methods, page 226; A uni- and multivariate analysis was also performed, on 
the adenocarcinomas, to look for predictors of short OS. 
Figure 4, page 228: The Kaplan Meier curve is erroneous. A correct version 
is presented in the Chapter 4.2, Figure 10, page 34. 
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